Chimeric antibodies were constructed in which the murine variable region of anti-colorectal cancer monoclonal antibody C017-lA was joined with human'y, -y2, 'y3, and y4 constant regions. Human-mouse chimeric proteins were compared with the parental murine IgG2a antibody C017-lA for their ability to participate in tumor-cell destruction by human and murine effector cells in antibody-dependent cell-mediated cytotoxicity (ADCC) assays. All of the chimeric antibodies showed different degrees of ADCC with human lymphocytes, monocytes, and granulocytes and with murine macrophages. Monocytes and macrophages were able to utilize the chimeric IgG1 and, to a lesser degree, IgG4 and IgG3 antibodies to lyse tumor-cell targets in ADCC assays. The chimeric IgG1 and IgG4 antibodies were nearly as effective as the parental C017-1A antibody in inhibiting tumor growth in nude mice. These data indicate that chimeric IgG1 antibody is superior in its antitumor activity.
superior in its antitumor activity.
Monoclonal antibody (mAb) C017-1A was developed in 1978 (1, 2) and, after characterization of its antitumor activities (3, 4) and of its selective binding to colon carcinoma cells (5, 6) , was used in clinical trials by Sears et al. (7, 8) . C017-1A is of the IgG2a isotype and is active in antibody-dependent cell-mediated cytotoxicity (ADCC) assays with murine (3, 9, 10) and human (9-13) effector cells. This mAb also inhibits the growth of human tumor xenografts in nude mice (3) . In patients with colon and pancreatic cancer treated with mAb C017-1A, complete and partial remissions have been described (7, 8, (14) (15) (16) (17) . However, murine immunoglobulins administered to humans have a short half-life (12-18 hr) and induce an anti-mouse immunoglobulin response (7, 8, 18) . For these reasons, recombinant DNA techniques have been used to construct chimeric mAbs in which the human constant (C) region of choice is linked to the murine variable (V) region (19) (20) (21) . A chimeric C017-1A protein has been constructed with the human C,,3 region (22) , and its characteristics have been described (23, 24) . Recently, we used the cloned murine V region of C017-1A to construct chimeric molecules with human CVi, C,,2, and C, regions. The availability of the series of chimeric mAbs with the same binding specificity permits direct comparison of all four human IgG isotypes for their effects in vitro and in vivo on human tumor-cell targets. Such analyses may provide a rationale for the selection of the most promising chimeric mAbs for clinical application.
MATERIALS AND METHODS
Chimeric Proteins. Methods for construction and characterization of yl, y2, 'y3, and 'y4 chimeric antibodies have been detailed (24) . In brief, the functionally rearranged heavy-and light-chain V genes of hybridoma 17-1A were isolated and inserted into expression vectors containing genomic DNA segments encoding human y heavy-chain and K light-chain C regions. As described previously (24) , transfection of these expression vectors containing mouse-human chimeric immunoglobulin genes into nonproducing mouse myeloma Sp2/0 cells resulted in stable cell lines producing IgG3(K) chimeric antibody. The V gene of 17-1A was also linked to the human yl, y2, and 'y4 C regions. The resulting chimeric heavy-chain genes were cotransfected with the chimeric light-chain genes into Sp2/0 cells to generate stable cell lines secreting IgGl(K), IgG2(K), and IgG4(K) antibodies, respectively. The transfected cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 15% (vol/vol) fetal bovine serum (FBS) and containing antibiotic G418 at 1 mg/ml, mycophenolic acid at 1 pug/ml, xanthine at 50 Ag/ml, and hypoxanthine at 2.5 ,ug/ml. The concentration of secreted antibody in the culture supernatant reached 10-15 tkg/ml.
Purification of Chimeric IgG. Chimeric IgGl(K), IgG2(c), and IgG4(K) antibodies were purified by passing the tissue culture supernatant over a protein A-Sepharose CL-4B (Pharmacia) column. Bound antibody was eluted in citrate buffer with a linear pH gradient of 3.5-5. Chimeric IgG3(K) antibody was purified by sequential ion-exchange column chromatography on DEAE-Sepharose 6B and Mono S (Pharmacia) (23) .
Cell Lines. U-937 is a myelomonocytic cell line derived from a patient with histiocytic lymphoma (25) maintained in RPMI-1640 medium supplemented with 10% FBS, 2 mM glutamine, and 50 gg of gentamicin per ml. Colorectal carcinoma cell lines SW948 (colon) and SW707 (rectal) (3) and melanoma cell line WM164 (26, 27) have been described. These cell lines were maintained in Leibowitz' L15 medium (Hazelton Research Products, Denver, PA) containing 10% FBS, 2 mM glutamine, and 50 ,ug of gentamicin per ml.
Isolation of Effector Cells. Enriched preparations of human monocytes were obtained from normal donors by adherence selection of Ficoll-Paque-purified (28) peripheral blood leukocytes (PBLs) on gelatin/fibronectin-coated flasks (29) . Natural killer/killer (NK/K) cells contaminating the monocyte preparations were lysed by incubation with anti-Leu-llb mAb and rabbit complement (29) . Nonadherent leukocytes were obtained after three 1-hr adsorption periods on plastic surfaces. Human granulocytes were isolated from peripheral blood of healthy donors. The blood was mixed with 5% (wt/vol) Dextran T70 (Pharmacia, Uppsala, Sweden) in 0.9% NaCl (2.5 ml per 10 ml of blood) and incubated for 1 hr at 370C. Leukocyte-rich plasma was then collected and centrifuged at 650 x g for 15 min at room temperature on disconAbbreviations: mAb, monoclonal antibody; ADCC, antibodydependent cell-mediated cytotoxicity; PBL, peripheral blood leukocyte; NK cell, natural killer cell; FcR, receptor for Fc part of immunoglobulin; C, constant; V, variable; FITC, fluorescein isothiocyanate; E/T ratio, effector-to-target cell ratio; IFN-'y, interferon y.
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tinuous density gradients consisting of Ficoll-Paque (2.0 ml, upper layer) and Histopaque 1119 (Sigma) (3 ml, lower layer) in 15-ml tubes. Cells were harvested from the interface between Ficoll-Paque and Histopaque 1119 and resuspended in RPMI-1640 with 10% FBS (pH 7.4) after three washings. This suspension contained >98% granulocytes as judged by morphology of cells on stained slides. Thioglycolate-elicited murine peritoneal macrophages from 6-to 10-week-old CBA mice were prepared as described (5).
Flow Cytofluorometry. To detect binding of chimeric mAb to the receptor for the Fc portion of immunoglobulin (FcR), U-937 cells were treated with interferon y (IFN-y) (Interferon Sciences, New Brunswick, NJ) for 30 hr (30) and then incubated with chimeric mAb followed by fluorescein isothiocyanate (FITC)-conjugated goat antiserum to mouse F(ab')2 fragment or rabbit antiserum to human IgG or Fc. Fluorescence was detected in an Ortho Cytofluorograf connected to an Ortho 2150 data-handling system (Ortho Instruments).
Cytotoxicity Assays. Subconfluent tumor-cell monolayers were labeled with [11lln]indium oxine (29) (indium oxyquinone, 20 mCi/ml; Medi-Physics, Emeryville, CA; 1 Ci = 37 GBq). The cells were suspended and added in triplicate to U-bottomed 96-well Linbro microtiter plates at 104 cells per well in RPMI-1640 containing 2% FBS (referred to as ADCC medium), after which 100 ul of mAb in the same medium was added.
[3H]Thymidine-release assays were carried out as described (31) . Negative controls were murine anti-influenza mAbs (IgG2a) kindly provided by W. Gerhard (The Wistar Institute). Effector cells were added at the predefined effector-to-target (E/T) ratio in ADCC medium, and plates were incubated at 37°C in humidified 5% C02/95% air for 18 
RESULTS
Binding of Chimeric mAbs to FcR. Control murine mAb C017-1A bound to the high-affinity FcR of -interferontreated U-937 cells (30) and was detected only by FITCconjugated goat anti-mouse F(ab')2 (Fig. 1) . Binding levels were similar among chimeric mAbs with human yl, y3, and y4 C regions, and binding was detectable with FITC-conjugated anti-human and anti-mouse sera (Fig. 1) . Little Immunology: Steplewski et al.
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I similar low levels, with an average of about 10% specific lysis at all three E/T ratios ( Fig. 2A) . In a similar experiment using SW948 colon carcinoma cells as targets (Fig. 2B) , the control murine mAb C017-1A gave 12.3%, 17.0%, and 44.5% lysis at E/T ratios of 10:1, 20:1, and 50:1, respectively. Again, IgG1 chimeric antibody had the highest ADCC activity with 13.0% lysis at an E/T ratio of 10:1, 22.0% at 20:1, and 48.3% at 50: 1. IgG2, IgG3, and IgG4 were again much less reactive with PBLs against SW948 colon carcinoma cells. Spontaneous release ranged from 4% to 8% (average of 7%). When human lymphocytes depleted of monocytes by adherence selection of PBLs were used as effector cells, two antibody groups could be distinguished, C017-1A and chimeric IgG1 and IgG2, which kill well, and chimeric IgG3 and IgG4, which were not as effective (Fig. 3) . At an E/T ratio of 50:1, IgG1 and IgG2 gave 25% lysis, where spontaneous release was 5.6% (data not shown).
Human monocyte preparations obtained from normal donors by adherence selection of PBLs on a gelatin/fibronectin surface contained 2-10% lymphocytes. The use of anti-Leulib mAb and complement totally abrogated NK-cell activity as tested on K562 erythroleukemia cells (results not shown). The NK-depleted monocyte preparation exhibited a significant level of ADCC with mAb C017-1A, ranging from 9% at an E/T ratio of 10:1 to 29% at an E/T ratio of 100:1 (Fig. 4) . Chimeric IgG1 had a similar ability to lyse target cells (13.5-25% lysis, depending on E/T ratio; Fig. 4 ). The other chimeras were lytic in the following relative order (according to release at the highest E/T ratio): IgG4 (5-25%), IgG2 (8-15%), and IgG3 (4-12%). Spontaneous release was 4-8.1%.
Human monocytes cultured for 2 days in vitro differentiate into macrophages and express higher levels of FcR (11, 12) . Such 2-day-old monocytes were active in ADCC assays with control mAb C017-1A (35.5%) and with chimeric IgG1 (52%) but were much less active with the IgG4, IgG2, and IgG3 chimeras (23%, 12%, and 10%, respectively). The presence of IFN-y (500 units/ml) in the monocyte culture increased the level of lysis for mAb C017-1A to 67.5%, for chimeric IgG1 to 78%, for chimeric IgG4 to 53%, for chimeric IgG2 to 36%, and for chimeric IgG3 to 35% (Fig. 5) , under conditions where spontaneous release was 7.6%.
Freshly isolated human granulocytes showed only lowlevel ADCC activity with chimeric mAbs in a 6-hr 11'Inrelease assay (Fig. 6) Fig. 2. pecially with chimeric IgG1 (9-25% with IFN-'y at 200 units/ml and 26% with IFN-y at 1000 units/ml; Fig. 6 ).
Murine Macrophage ADCC. Thioglycolate-elicited macrophages are known to be highly efficient in killing target cells with mAb (5, 32) . However, it has remained unclear whether human Fc can react with murine FcR. Therefore, we tested the chimeric proteins and murine macrophages for ADCC activity against human colon carcinoma cell line SW948 in a [3H]thymidine-release assay. mAb C017-1A and chimeric IgG1 lysed a similar percentage of cells, although C017-1A was always slightly more active (Fig. 7) . IgG4 induced about 50% lysis, whereas IgG3 was much less effective (25-30%) and IgG2 was totally inactive. The spontaneous release was always in the range 3.5-14% (average 12%). Similar results were obtained in three consecutive experiments.
Inhibition of Tumor Growth. mAb C017-1A is known to inhibit growth of SW948 colon carcinoma cells xenografted into nude mice (5) . Under the same conditions and antibody dosage, chimeric IgG1 and IgG4 were most efficient in inhibiting tumor growth, whereas chimeric IgG2 and IgG3 were ineffective (Fig. 8) .
DISCUSSION
The chimeric mAbs described in this study contain the murine V region of mAb C017-1A and human C domain yl, y2, y3, or y4 (19, 22, 24) . The chimeric antibodies retained the binding specificity of mAb C017-IA (24) . Besides "transfectoma"-derived chimeric mAbs with hapten specificities (20, 21) , similar chimeras have been produced that show antitumor activities (33) (34) (35) (36) (37) (38) . The data derived from these and similar experiments indicate that chimeric mAbs have biological functions (34, 38 From these data, it is clear that the cells with FcR types I, II, and III, such as human monocytes, macrophages, polymorphonuclear cells, and murine macrophages, are able to utilize chimeric IgG1 mAb and, to a lesser degree, chimeric IgG3 and IgG4 mAbs for lysis of human tumor-cell targets in ADCC. IFN-y-induced expression of FcR on monocytes and granulocytes correlated with highest ADCC activity of chimeric IgG1. However, we do not know whether this increased killing is due only to higher FcR expression or whether IFN-y also has the ability to increase killing by other mechanisms.
Since mouse macrophages were also able to efficiently kill human tumor cells with some of the chimeric proteins, especially the IgG1 and IgG4 chimeras, we tested all four chimeric mAbs for their ability to inhibit growth of human *N,., tumor xenografts in nude mice. The chimeric IgG1 and IgG4 mAbs were as effective as the parental C017-1A in inhibiting tumor growth. IgG2 and IgG3 chimeras were not effective in the nude mouse system, as expected from their minimal participation in ADCC with murine macrophages, which are known effector cells for tumor destruction in this system (31) .
The data indicate that IgG1 chimeric antibody is superior in its antitumor activity and may be considered for immunotherapeutic application.
